Portfolio of the eHealth Projects in the FP7. FP7 is the EU's chief instrument for funding scientific research and technological development over the period 2007 to 2013.
Adverse Drug Events (ADE) due to product safety problems, and medication errors due to human factors (HF) are a major Public Health issue. They endanger the patients¿ safety and originate considerable extra hospital costs. Healthcare ICT applications should help reducing the prevalence of preventable ADE, by providing healthcare professionals and patients with relevant knowledge (guidelines, recommendations, etc.).
According to recent studies, Risks Against Patient Safety (RAPS) represent one of the most important factors of dead in hospitals: during therapy, more then 8% of patients recovered in hospitals suffer for additional disease that in almost 50% of the cases produce either dead or significant additional health problems. RAPS occur in any stage of the patient care process.
epSOS stands for Smart Open Services for European Patients and focuses on Interoperable Patient Summaries and ePrescribing. It involves 27 beneficiaries from 12 EU-member states, including ministries of health, national competence centres and industry. The project will deliver and validate interoperable patients' summaries and ePrescription solutions, which will enable the exchange of data in a safe, secure and interoperable manner also across national borders. The solutions (applications/services) will be based on existing national systems.
The Virtual Physiological Human Network of Excellence (VPH NoE) proposal has been designed with 'service to the community' of VPH researchers as its primary purpose. Its aims range from the development of a VPH ToolKit and associated infrastructural resources, through integration of models and data across the various relevant levels of physiological structure and functional organisation, to VPH community building and support.
Heart failure accounts for almost a quarter of all admissions to hospital for cardiovascular events, has a high mortality (median survival around 18 months), and places a great burden on all healthcare systems, with estimated direct costs of £905m (1350m) in the United Kingdom in 2000, 2% of total NHS expenditure.
Nearly four million osteoporotic bone fractures cost the European health system more than 30 billion Euro per year. This figure could double by 2050. After the first fracture, the chances of having another one increase by 86%. We need to prevent osteoporotic fractures. The first step is an accurate prediction of the patient-specific risk of fracture that considers not only the skeletal determinants but also the neuromuscular condition.